Patents by Inventor Daniel La

Daniel La has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
    Publication number: 20260098053
    Abstract: Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (1-I) and methods of using the compounds, e.g. in the treatment of CNS-related disorders.
    Type: Application
    Filed: June 11, 2025
    Publication date: April 9, 2026
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison, Marshall Lee Morningstar
  • COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
    Publication number: 20260078143
    Abstract: Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: August 6, 2025
    Publication date: March 19, 2026
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
  • Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof
    Patent number: 12565492
    Abstract: Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
    Type: Grant
    Filed: October 14, 2025
    Date of Patent: March 3, 2026
    Assignee: Triana Biomedicines, Inc.
    Inventor: Daniel La
  • ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF
    Publication number: 20260042752
    Abstract: Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
    Type: Application
    Filed: October 14, 2025
    Publication date: February 12, 2026
    Inventor: Daniel La
  • C7 SUBSTITUTED OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20250388622
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: May 13, 2025
    Publication date: December 25, 2025
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • Compositions and methods for treating CNS disorders
    Patent number: 12421275
    Abstract: Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: September 23, 2025
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
  • C7 substituted oxysterols and methods of use thereof
    Patent number: 12331070
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: June 17, 2025
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
    Publication number: 20250171492
    Abstract: Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8 and R13 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: July 12, 2024
    Publication date: May 29, 2025
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
  • C7 SUBSTITUTED OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20240300995
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: February 1, 2024
    Publication date: September 12, 2024
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
    Publication number: 20240150393
    Abstract: Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: June 5, 2023
    Publication date: May 9, 2024
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
  • C7 substituted oxysterols and methods of use thereof
    Patent number: 11926646
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: March 12, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • CYP46A1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230312522
    Abstract: Described herein are compounds that act as CYP46A1 inhibitors, compositions comprising these compounds, and methods for their use in treating neurodegenerative diseases and the like, or a pharmaceutically acceptable salt thereof. The present disclosure relates to compounds represented by the formula wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 25, 2023
    Publication date: October 5, 2023
    Inventors: Steven Mischke, Allen Taylor Hopper, Daniel La, Maria-Jesus Blanco-Pillado
  • Compositions and methods for treating CNS disorders
    Patent number: 11718642
    Abstract: Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g. in the treatment of CNS-related disorders.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 8, 2023
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
  • COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
    Publication number: 20230085354
    Abstract: Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (1-I) and methods of using the compounds, e.g, in the treatment of CNS-related disorders.
    Type: Application
    Filed: June 29, 2020
    Publication date: March 16, 2023
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison, Marshall Lee Morningstar
  • COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20220332699
    Abstract: Described herein are compounds that act as CYP46A1 inhibitors, compositions comprising these compounds, and methods of their use into treating neurodegenerative diseases and the like, or a pharmaceutically active salt thereof. The present invention relates to compounds represented by the formula wherein each symbol is as defined in the specification, or a pharmaceutically active salt thereof.
    Type: Application
    Filed: May 24, 2020
    Publication date: October 20, 2022
    Inventors: Allen Taylor Hopper, Steven Mischke, Daniel La
  • COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
    Publication number: 20220315621
    Abstract: Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8 and R13 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 6, 2022
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
  • Oxysterols and methods of use thereof
    Patent number: 11279730
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3 and R6, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: March 22, 2022
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin, Daniel La
  • C7 SUBSTITUTED OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20220081465
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: September 15, 2021
    Publication date: March 17, 2022
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • C7 substituted oxysterols and methods of use thereof
    Patent number: 11149056
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1b, n, R2A, R2b, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: September 30, 2017
    Date of Patent: October 19, 2021
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20210147468
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3 and R6, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: July 30, 2020
    Publication date: May 20, 2021
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin, Daniel La